Bisphosphonates

BMJ. 2024 Aug 21:386:e076898. doi: 10.1136/bmj-2023-076898.

Authors

Emma Billington¹, Fariba Aghajafari², Elaine Skulsky³, Gregory A Kline^{4

5}

Affiliations

¹ Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary AB, Canada T2T5C7.
² Department of Family Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary.
³ Calgary, Canada.
⁴ Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary AB, Canada T2T5C7 gakline@ucalgary.ca.
⁵ Dr. David Hanley Osteoporosis Centre, Cumming School of Medicine, University of Calgary.

PMID: 39168493
DOI: 10.1136/bmj-2023-076898

No abstract available

Publication types

Case Reports
Review

MeSH terms

Aged
Bisphosphonate-Associated Osteonecrosis of the Jaw / etiology
Bisphosphonate-Associated Osteonecrosis of the Jaw / prevention & control
Bone Density Conservation Agents* / adverse effects
Bone Density Conservation Agents* / therapeutic use
Diphosphonates* / adverse effects
Diphosphonates* / therapeutic use
Female
Humans
Osteoporosis / drug therapy

Substances

Bone Density Conservation Agents
Diphosphonates